ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2167

24-week, Post-Marketing Surveillance Analysis of Upadacitinib in Japanese Patients with Rheumatoid Arthritis (Encore1)

Tatsuya Atsumi1, Nami Okamoto2, Nobunori Takahashi3, Naoto Tamura4, Atsuo Nakajima5, Ayako Nakajima6, Takao Fujii7, Hiroaki Matsuno8, Takeshi Kawaberi9, Naomi Sunaga9, Yuki Tsujita10, Sumi Chonan9, Masataka Kuwana11 and Michiaki Takagi12, 1Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan, 2Department of Paediatrics, Osaka Rosai Hospital, Sakai-city, Japan, 3Department of Orthopedic Surgery, Aichi Medical University, Nagakute, Japan, 4Department of Internal Medicine and Rheumatology, Juntendo University Faculty of Medicine, Tokyo, Japan, 5Ueno Dialysis Clinic, Taito-ku, Japan, 6Center for Rheumatic Diseases, Mie University Hospital, Tsu, Japan, 7Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan, 8Matsuno Clinic for Rheumatic Diseases, Toyama City, Japan, 9AbbVie GK, Minato-ku, Japan, 10Abbvie GK, Minato City Tokyo, Japan, 11Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 12Department of Orthopaedic Surgery, Yamagata University Faculty of Medicine, Yamagata, Japan

Meeting: ACR Convergence 2023

Keywords: Disease-Modifying Antirheumatic Drugs (Dmards), rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2141–2176) RA – Treatments Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Upadacitinib (UPA) was approved in 2020 in Japan for the treatment of “Rheumatoid arthritis (RA) patients with inadequate response to conventional therapy, including inhibition of structural damage progression”. All-case post-marketing Surveillance (PMS) in Japan was started at the same time of the market launch and is currently collecting data up to 3-years (24-week data for solicited events). In Japanese label, UPA15 mg should be orally administered once daily for adult RA patients. UPA 7.5 mg may be acceptable for some patients according to their condition.

Methods: This ongoing PMS includes all patients with RA prescribed with UPA since April 2020. An interim analysis of PMS was performed to evaluate the safety and the effectiveness (disease activity) of UPA for 24 weeks.

Results: As of August 15, 2022, 2878 patients were enrolled, with 2,106 and 1,482 patients included in the safety (mean age=65.3 years old; >65 years old=58.5%; female=80.2%; mean RA duration=12.0 years) and efficacy analysis set, respectively (Table 1). In the safety analysis set, 1,694 (80.4%) continued UPA treatment for 24 weeks. UPA doses at onset were 7.5mg/day in 540 (25.6%), 15mg/day in 1,549 (73.6%) of patients in the safety analysis set, respectively. At baseline, 44.4% and 41.0% of patients in the safety analysis set received methotrexate (MTX) and glucocorticoid, respectively, and 22.4% had mild or greater renal failure. Most common comorbidities were osteoporosis, hypertension, and gastroesophageal reflux disease. AEs and serious AEs (SAEs) occurred in 464 (22.0%) and 99 (4.7%) patients, respectively. In the 1,299 patients receiving MTX >8 mg/week for ≥3 months,2 AEs occurred in 268 (20.6%) and SAEs in 47 (3.6%). In the 806 patients not receiving MTX > 8mg/week for ≥3 months, AEs occurred in 196 (24.3%) and SAEs in 52 (6.5%) (Table 2). Ten deaths were reported, with causes including lung tumor, subarachnoid hemorrhage, organizing pneumonia, bacterial pneumonia, pneumocystis jirovecii, COVID-19 and unknown. Serious infections were reported in 37 (1.8%) patients. Herpes zoster in 69 (3.3%), impaired liver function in 59 (2.8%), serious cytopenia in 3 (0.1%), renal impairment in 11 (0.5%), malignancy in 10 (0.5%), cardiovascular event in 8 (0.4%), interstitial pneumonia in 5 (0.2%), and venous thromboembolism (VTE) in 1 (0.0%) were reported, respectively (Table 3). 6 of 10 patients with malignancies were diagnosed within 2 months of UPA initiation. 621 patients were assessed in DAS28-CRP, of which 488 (78.6%) achieved LDA or CR and 382 (61.5%) achieved CR.

Conclusion: The 24-week interim analysis of all-case PMS in Japan showed that more than half of the patients receiving UPA are over aged 65 years or older. Although the mean age is higher than that of patients in clinical studies, the safety profile was consistent with clinical trials, and no new safety signals were identified.3,4 The safety and efficacy data from this real-world setting will continue to be collected to assess for RA patients treated with UPA in Japan.
References
1 Mod Rheumatol suppl 2023(33): S179, presented at the JCR2023, Apr 24–26, Japan.
2 JCR guideline for proper use of UPA in PMS
3 Burmester, et al. RMD Open 2023;9: e002735
4 Yamaoka, et al. Drug Saf. 2021 Jun;44(6):711-722.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: T. Atsumi: AbbVie, 5, 6, Alexion, 5, 6, Astellas, 5, 6, Boehringer-Ingelheim, 2, Bristol-Myers Squibb, 6, Chugai, 5, 6, Daiichi Sankyo, 5, 6, Eisai, 5, 6, Eli Lilly, 5, 6, Gilead, 5, 6, GSK, 2, 5, Merck Sharp & Dohme, 2, 6, Mitsubishi Tanabe Pharma, 5, 6, Otsuka, 5, 6, Pfizer, 5, 6, Sanofi/Genzyme, 2, 6, Takeda, 5, 6, UCB, 5, 6; N. Okamoto: None; N. Takahashi: AbbVie/Abbott, 6, Asahi-Kasei, 6, Astellas, 6, Bristol-Myers Squibb(BMS), 6, Chugai, 6, Daiichi Sankyo, 6, Eisai, 6, Eli Lilly, 6, Janssen, 6, Mitsubishi Tanabe, 6, Novartis, 6, Pfizer, 6, Sanofi, 6, UCB, 6; N. Tamura: AbbVie/Abbott, 5, 6, Asahi-Kasei, 5, 6, Ayumi, 5, 6, Boehringer-Ingelheim, 5, 6, Chugai, 5, 6, Eisai, 5, 6, Janssen, 5, 6, Mitsubishi Tanabe, 5, 6, Novartis, 5, 6, Taisho, 5, 6; A. Nakajima: None; A. Nakajima: AbbVie/Abbott, 5, 6, Asahi-Kasei, 5, 6, AstraZeneca, 5, 6, Ayumi, 5, 6, Bristol-Myers Squibb(BMS), 5, 6, Chugai, 5, 6, Eisai, 5, 6, Eli Lilly, 5, 6, GlaxoSmithKlein(GSK), 5, 6, Janssen, 5, 6, Kissei, 5, 6, Mitsubishi Tanabe, 5, 6, Nippon Kayaku, 5, 6, Novartis, 5, 6, Pfizer, 5, 6, Taisho, 5, 6; T. Fujii: AbbVie/Abbott, 5, 6, Asahi-Kasei, 5, 6, Astellas, 5, 6, Boehringer-Ingelheim, 5, 6, Chugai, 5, 6, Eisai, 5, 6, Eli Lilly, 5, 6, GlaxoSmithKlein(GSK), 5, 6, Janssen, 5, 6, Mitsubishi Tanabe, 5, 6, Ono, 5, 6, Pfizer, 5, 6, UCB, 5, 6; H. Matsuno: None; T. Kawaberi: AbbVie/Abbott, 3, 11; N. Sunaga: AbbVie/Abbott, 3, 11; Y. Tsujita: AbbVie/Abbott, 3, 11; S. Chonan: AbbVie/Abbott, 3, 11; M. Kuwana: AbbVie/Abbott, 6, Asahi-Kasei, 5, 6, Astellas, 6, AstraZeneca, 2, Boehringer-Ingelheim, 2, 5, 6, Chugai, 2, 5, 6, Corbus, 2, Eisai, 6, GlaxoSmithKlein(GSK), 2, Horizon, 2, Janssen, 6, Kissei, 2, MBL, 2, 5, Mitsubishi Tanabe, 2, 5, 6, Mochida, 2, 6, Nippon Shinyaku, 6, Ono, 5, 6; M. Takagi: None.

To cite this abstract in AMA style:

Atsumi T, Okamoto N, Takahashi N, Tamura N, Nakajima A, Nakajima A, Fujii T, Matsuno H, Kawaberi T, Sunaga N, Tsujita Y, Chonan S, Kuwana M, Takagi M. 24-week, Post-Marketing Surveillance Analysis of Upadacitinib in Japanese Patients with Rheumatoid Arthritis (Encore1) [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/24-week-post-marketing-surveillance-analysis-of-upadacitinib-in-japanese-patients-with-rheumatoid-arthritis-encore1/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/24-week-post-marketing-surveillance-analysis-of-upadacitinib-in-japanese-patients-with-rheumatoid-arthritis-encore1/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology